Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock, up previously from $24.00.
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock, up previously from $30.00.
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $30.00 price target on the stock, up previously from $18.00.